Causal associations between gut microbiota and type 2 diabetes mellitus subtypes: a mendelian randomization analysis
Ruan Z, Liu J, Zhao J
BMC Endocr Disord. 2025;25(1):79.
Leggi
Breaking news
AIFA: Riclassificazione del medicinale per uso umano “Awiqli” (insulina Icodec) classe di rimborsabilità: A (Determina n. 273/2025)
25/03/2025
Leggi
AIFA: Modifica dei prescrittori per i medicinali a base dei principi attivi evolocumab, alirocumab e inclisiran, autorizzati con regime di fornitura RRL. (Determina n. 252/2025)
21/03/2025
Leggi
Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: a real world analysis
Tsur A, Cahn A, Hanoch L, Pollack R
Diabetes Obes Metab. Pub. online 14 Mar 2025.
Leggi
AIFA: Rinegoziazione del medicinale per uso umano «Synjardy». (Determina n. 216/2025)
15/03/2025
Leggi
AIFA: Rinegoziazione del medicinale per uso umano «Trulicity. (Determina n. 218/2025)
15/03/2025
Leggi
Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: a real-world retrospective study
Costa S, Miranda C, Elefante A, et al.
Diabetes Obes Metab. Pub. online 6 Mar 2025.
Leggi
Automated insulin delivery in elderly with type 1 diabetes: a prespecified analysis of the extension phase
Kudva YC, Henderson RJ, Kanapka LG, et al.
Diabetes Technol Ther. Pub. online 11 Mar 2025.
Leggi
An overview of obesity-related complications: the epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Blüher M
Diabetes Obes Metab. Pub. online 11 Mar 2025.
Leggi
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: a post hoc analysis of the SURPASS clinical trial programme
Bergman BK, Rosenstock J, Garvey WT, et al.
Diabetes Obes Metab. Pub. online 13 Mar 2025.
Leggi